The modulatory impact of recombinant human interleukin-6 on the immune system of cancer patients

Autor: Pieter Limburg, Elisabeth G.E. de Vries, Lou F. M. H. de Leij, Jacob Pietens, Nanno Mulder, Judith Nieken
Přispěvatelé: Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Rok vydání: 1999
Předmět:
Male
Cancer Research
medicine.medical_treatment
immunomodulation
Leukocyte Count
Immunology and Allergy
ACTIVATED KILLER-CELLS
Melanoma
TUMOR-NECROSIS-FACTOR
biology
NATURAL-KILLER
Middle Aged
I TRIAL
Prognosis
Kidney Neoplasms
Recombinant Proteins
Monokine
Survival Rate
medicine.anatomical_structure
Cytokine
PHASE PROTEIN RESPONSE
Cytokines
Tumor necrosis factor alpha
Female
Antibody
Adult
renal cell carcinoma
GROWTH-FACTOR
Adolescent
Immunology
malignant melanoma
Immunoglobulins
Disease-Free Survival
Immune system
White blood cell
medicine
Humans
human
Carcinoma
Renal Cell
Aged
Pharmacology
business.industry
Interleukin-6
Tumor Necrosis Factor-alpha
Granulocyte-Macrophage Colony-Stimulating Factor
Immunotherapy
medicine.disease
Lymphocyte Subsets
MEGAKARYOCYTE DEVELOPMENT
BLOOD T-CELLS
STIMULATING FACTOR
PROGENITOR CELLS
biology.protein
business
Follow-Up Studies
Zdroj: Journal of Immunotherapy, 22(4), 363-370. LIPPINCOTT WILLIAMS & WILKINS
ISSN: 1524-9557
1053-8550
Popis: To investigate the immunomodulatory impact of low-dose recombinant human interleukin-6 (rhIL-6), we examined 15 patients with metastatic renal cell carcinoma or malignant melanoma receiving rhIL-6 as an antitumor agent in a phase II trial. RhIL-6 (150 micrograms) was administered subcutaneously (s.c.) once daily for 42 consecutive days. Immunologic parameters were measured throughout therapy and at follow-up. No changes in white blood cell counts were noted. Lymphocyte subsets did not alter, nor did their expression of CD25 and HLA-DR. Immunoglobulins were unaffected. Levels of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha and IL-1 beta remained below detection limits. Theoretically, subtle immunologic alterations might have been masked by increases in plasma volume, known to occur after start of therapy. Using previously published data concerning plasma volume changes in these patients, part of immunologic data were corrected for concurrent hemodilution, showing a 39% +/- 17% increase in monocytes (mean change +/- SEM [standard error of mean]; p < 0.03) within 1 week of therapy, while lymphocytes tended to increase. However, the absence of appreciable increases in cell activation markers and in monokine levels indicates insufficient immune activation, probably underlying the lack of objective antitumor responses (6 x stable, 9 x progressive disease) in these patients. In conclusion, the immunomodulatory impact of rhIL-6, if present at all, remains very limited.
Databáze: OpenAIRE
Externí odkaz: